Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
7.27
+0.40 (5.90%)
At close: Apr 17, 2025, 4:00 PM
7.26
0.00 (-0.07%)
After-hours: Apr 17, 2025, 7:36 PM EDT
Intellia Therapeutics Revenue
In the year 2024, Intellia Therapeutics had annual revenue of $57.88M with 59.55% growth. Intellia Therapeutics had revenue of $12.87M in the quarter ending December 31, 2024, a decrease of -771.57%.
Revenue (ttm)
$57.88M
Revenue Growth
+59.55%
P/S Ratio
12.35
Revenue / Employee
$143,615
Employees
403
Market Cap
748.43M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 57.88M | 21.60M | 59.55% |
Dec 31, 2023 | 36.28M | -15.85M | -30.40% |
Dec 31, 2022 | 52.12M | 19.07M | 57.69% |
Dec 31, 2021 | 33.05M | -24.94M | -43.01% |
Dec 31, 2020 | 57.99M | 14.89M | 34.55% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
NTLA News
- 4 days ago - Final Deadline Today for the Intellia Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - NTLA - PRNewsWire
- 8 days ago - SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - PRNewsWire
- 9 days ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - GlobeNewsWire
- 15 days ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit – NTLA - GlobeNewsWire
- 15 days ago - Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy - GlobeNewsWire
- 22 days ago - Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication - Seeking Alpha
- 23 days ago - Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy - GlobeNewsWire
- 5 weeks ago - Intellia Therapeutics, Inc. (NTLA) Barclays 27th Annual Global Healthcare Conference (Transcript) - Seeking Alpha